Exclusive special offer and discount title banner vector image

GLOBAL SKIN CANCER DIAGNOSTICS MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Global Skin Cancer Diagnostics Market by Type (Melanoma, Non-melanoma) Market by Gender (Male, Female) Market by Screening Type (Skin Biopsy, Dermatoscopy, Lymph Node, Biopsy Imaging Tests, Blood Tests) by Geography

REQUEST CUSTOMIZATION

MARKET OVERVIEW

The global skin cancer diagnostics market is expected to reach $7252.15 million by 2032, growing at a CAGR of 7.13% during the forecast period 2023-2032. The base year considered for the studied market is 2022, and the estimated period is between 2023 and 2032. The market study has also analyzed the impact of COVID-19 on the global skin cancer diagnostics market qualitatively as well as quantitatively.

Skin cancer diagnostics refers to the segment of the healthcare industry that encompasses various products, technologies, and services utilized for the detection, diagnosis, and assessment of skin cancer. Skin cancer originates in the skin cells and can manifest in different forms, such as basal cell carcinoma, squamous cell carcinoma, and melanoma. Skin cancer diagnostics methods typically involve a combination of clinical examination, visual inspection, dermoscopy, and histopathological analysis of tissue samples.

Read our latest blog on the Skin Cancer Diagnostics Market

GROWTH ENABLERS

Key enablers of the global skin cancer diagnostics market growth: 

  • Increasing prevalence of skin cancer
    • Over the past few decades, the occurrence of both melanoma and non-melanoma skin cancers has been steadily increasing, making skin cancer one of the most prevalent forms of cancer. According to the World Health Organization (WHO), in the year 2020, the estimated number of newly diagnosed cases of skin cancer exceeded 1.5 million.
    • Furthermore, as per the European Commission, skin melanoma was responsible for 4% of the total new cancer diagnoses in EU-27 countries in the year 2020. Additionally, it accounted for 1.3% of all cancer-related fatalities. In Europe, skin cancer ranks as the sixth most commonly diagnosed cancer.
    • As the prevalence of various types of cancer, in addition to skin cancer, rises globally, it is anticipated that the global market for skin cancer diagnostics will subsequently grow during the forecast period.
  • Growing awareness about skin cancer diagnosis & treatment
  • Technological advancements in skin cancer diagnostic products

GROWTH RESTRAINTS

Key growth restraining factors of the global skin cancer diagnostics market:
  • High costs associated with skin cancer treatments
    • Skin cancer treatment expenses can be substantial, particularly for individuals with advanced or metastatic conditions. The range of available treatment options encompasses surgical procedures, radiation therapy, chemotherapy, immunotherapy, and various others. 
    • The overall expenses associated with skin cancer treatment vary based on multiple factors, such as the specific type of skin cancer, the stage of cancer, and the treatment approach recommended by the physician.
    • Moreover, estimations suggest that the average expenditure for treating skin cancer in the United States falls within the range of $400 to $50,000. Similarly, in Europe, the average cost of skin cancer treatment is estimated to range from €200 to €20,000.
    • Consequently, the substantial health and economic burden associated with skin cancer treatment is expected to pose a significant challenge to the expansion of the global skin cancer diagnostics market over the projected period.
  • Stringent regulatory framework
  • Lack of skilled medical professionals

KEY MARKET TRENDS

Global Skin Cancer Diagnostics Market | Top Trends

  • In the field of skin cancer diagnosis, artificial intelligence (AI) has emerged as a revolutionary tool, with dermatologists playing a crucial role in its associated advancement and integration. The utilization of AI holds great potential in enhancing the precision and efficiency of skin cancer diagnosis, ultimately resulting in improved patient outcomes. 
  • The application of technology in detecting skin cancer has the capability to enhance the quality of life, lower healthcare expenses by reducing unnecessary procedures, and facilitate greater access to high-quality skin assessment.

MARKET SEGMENTATION

Market Segmentation – Type, Gender, and Screening Type –  

Market by Type:

  • Melanoma
  • Non-Melanoma
    • Non-melanoma is anticipated to be the fastest-growing type in the market, with an anticipated CAGR of 7.45%. 
    • Non-melanoma skin cancer originates from skin cells and manifests as a collection of cancer cells known as malignant growth. It has the capacity to invade and damage surrounding tissue; however, the occurrence of metastasis to other body parts is uncommon in non-melanoma skin cancer. 
    • Basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma are different types of non-melanoma skin cancers.

Market by Gender:

  • Male
  • Female

Market by Screening Type:

  • Skin Biopsy
    • In 2022, the majority of the market share was captured by the skin biopsy segment under the screening type category. 
    • Skin biopsy, a medical procedure that involves the extraction of a small sample of skin tissue from the body, is the most commonly used material for screening. 
    • Due to its accuracy, reliability, and versatility, skin biopsy remains the gold standard for diagnosing skin cancer and plays a pivotal role in effective skin cancer screening and management. The demand for skin biopsies has grown to a large extent and is expected to augment further during the forecasted period. 
    • The procedure also provides a definitive diagnosis by allowing the examination of the suspicious skin lesion under a microscope. Moreover, it helps determine whether the lesion is cancerous, in addition to identifying the type of skin cancer and its characteristics, such as the stage and aggressiveness.
  • Dermatoscopy
  • Lymph Node
  • Biopsy Imaging Tests
  • Blood Tests

GEOGRAPHICAL STUDY

Geographical Study based on Four Major Regions: 

  • North America: The United States and Canada
    • North America is anticipated to be the largest regional market, with a share of 41.71% in 2022. 
    • The North America skin cancer diagnostics market has witnessed considerable growth due to heavy investments in the R&D of skin cancer diagnostics products by top players such as Dermlite LLC, Castle Biosciences Inc, and Dermtech Inc, operating in the region. In addition, the rapidly increasing cases of melanoma are also driving the market’s growth.
    • Furthermore, North America is at the forefront of the development of skin cancer diagnostics, presenting the region’s market with notable growth opportunities. 
  • Europe: The United Kingdom, Germany, France, Italy, Spain, Nordic Countries, Belgium, Poland, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

Major players in the global skin cancer diagnostics market:

  • F. Hoffmann-La Roche Ltd
  • Castle Biosciences Inc
  • DermTech Inc
  • Michelson Diagnostics Ltd
  • NeraCare GmbH
  • NV SkylineDx BV
  • BioMérieux SA

Key strategies adopted by some of these companies:

  • SkylineDx and NeraCare GmbH announced a partnership in April 2023 to jointly develop a test for helping life science companies in expediting the launch of crucial melanoma therapies.
  • SkylineDx BV launched the Merlin Assay, a CE-IVD test kit, in September 2022 across Europe. This assay accurately identifies melanoma patients at low risk of nodal metastasis, eliminating the need for sentinel lymph node biopsy (SLNB) surgery.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedType, Gender, Screening Type
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies AnalyzedAMLo Biosciences Limited, bioMérieux SA, Castle Biosciences Inc, DermLite LLC, DermTech Inc, F Hoffmann-La Roche Ltd, Michelson Diagnostics Ltd, NeraCare GmbH, SkylineDx BV, Veriskin Inc

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
    5. MAJOR MARKET FINDINGS
      1. INCREASING APPLICATION OF AI AND MACHINE LEARNING IN SKIN CANCER DIAGNOSIS TOOLS
      2. EXPANDING DEMAND FOR SKIN CANCER DIAGNOSTICS IN AUSTRALIA
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INCREASING PREVALENCE OF SKIN CANCER
      2. GROWING AWARENESS ABOUT SKIN CANCER DIAGNOSIS & TREATMENT
      3. TECHNOLOGICAL ADVANCEMENTS IN SKIN CANCER DIAGNOSTIC PRODUCTS
    2. KEY RESTRAINTS
      1. HIGH COSTS ASSOCIATED WITH SKIN CANCER TREATMENTS
      2. STRINGENT REGULATORY FRAMEWORK
      3. LACK OF SKILLED MEDICAL PROFESSIONALS
  4. KEY ANALYTICS
    1. PARENT MARKET ANALYSIS
    2. KEY MARKET TRENDS
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING
    5. MARKET CONCENTRATION ANALYSIS
    6. VALUE CHAIN ANALYSIS
      1. RESEARCH AND DEVELOPMENT
      2. MANUFACTURING
      3. MARKETING AND SALES
      4. DISTRIBUTION AND LOGISTICS
      5. TRAINING AND SUPPORT
  5. MARKET BY TYPE
    1. MELANOMA
    2. NON-MELANOMA
  6. MARKET BY GENDER
    1. MALE
    2. FEMALE
  7. MARKET BY SCREENING TYPE
    1. SKIN BIOPSY
    2. DERMATOSCOPY
    3. LYMPH NODE
    4. BIOPSY IMAGING TESTS
    5. BLOOD TESTS
  8. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET DRIVERS
      3. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
      4. KEY PLAYERS IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET
      5. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE SKIN CANCER DIAGNOSTICS MARKET DRIVERS
      3. EUROPE SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
      4. KEY PLAYERS IN EUROPE SKIN CANCER DIAGNOSTICS MARKET
      5. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        6. NORDIC COUNTRIES
          1. NORDIC COUNTRIES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        7. BELGIUM
          1. BELGIUM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        8. POLAND
          1. POLAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        9. REST OF EUROPE
          1. REST OF EUROPE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET DRIVERS
      3. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        5. INDONESIA
          1. INDONESIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        7. VIETNAM
          1. VIETNAM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET DRIVERS
      3. REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
      4. KEY PLAYERS IN REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET
      5. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  9. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. PRODUCT LAUNCHES & DEVELOPMENTS
      2. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. AMLO BIOSCIENCES LIMITED
      2. BIOMERIEUX SA
      3. CASTLE BIOSCIENCES INC
      4. DERMLITE LLC
      5. DERMTECH INC
      6. F. HOFFMANN-LA ROCHE LTD
      7. MICHELSON DIAGNOSTICS LTD
      8. NERACARE GMBH
      9. SKYLINEDX BV
      10. VERISKIN INC

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – SKIN CANCER DIAGNOSTICS

TABLE 2: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: GLOBAL MELANOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: GLOBAL MELANOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: GLOBAL NON-MELANOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: GLOBAL NON-MELANOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: GLOBAL MALE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: GLOBAL MALE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 12: GLOBAL FEMALE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 13: GLOBAL FEMALE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 14: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 15: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 16: GLOBAL SKIN BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 17: GLOBAL SKIN BIOPSY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 18: GLOBAL DERMATOSCOPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 19: GLOBAL DERMATOSCOPY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 20: GLOBAL LYMPH NODE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 21: GLOBAL LYMPH NODE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 22: GLOBAL BIOPSY IMAGING TESTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 23: GLOBAL BIOPSY IMAGING TESTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 24: GLOBAL BLOOD TESTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 25: GLOBAL BLOOD TESTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 26: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 27: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 28: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 29: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 30: KEY PLAYERS OPERATING IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET

TABLE 31: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 32: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 33: KEY PLAYERS OPERATING IN EUROPE SKIN CANCER DIAGNOSTICS MARKET

TABLE 34: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 35: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 36: KEY PLAYERS OPERATING IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET

TABLE 37: REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 38: REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 39: KEY PLAYERS OPERATING IN REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET

TABLE 40: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 41: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA

FIGURE 4: GROWTH PROSPECT MAPPING FOR EUROPE

FIGURE 5: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC

FIGURE 6: GROWTH PROSPECT MAPPING FOR MEXICO

FIGURE 7: MARKET CONCENTRATION ANALYSIS

FIGURE 8: VALUE CHAIN ANALYSIS

FIGURE 9: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 10: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY MELANOMA, 2023-2032 (IN $ MILLION)

FIGURE 11: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY NON-MELANOMA, 2023-2032 (IN $ MILLION)

FIGURE 12: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY GENDER, IN 2022

FIGURE 13: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY MALE, 2023-2032 (IN $ MILLION)

FIGURE 14: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY FEMALE, 2023-2032 (IN $ MILLION)

FIGURE 15: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY SCREENING TYPE, IN 2022

FIGURE 16: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY SKIN BIOPSY, 2023-2032 (IN $ MILLION)

FIGURE 17: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY DERMATOSCOPY, 2023-2032 (IN $ MILLION)

FIGURE 18: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY LYMPH NODE, 2023-2032 (IN $ MILLION)

FIGURE 19: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY BIOPSY IMAGING TESTS, 2023-2032 (IN $ MILLION)

FIGURE 20: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY BLOOD TESTS, 2023-2032 (IN $ MILLION)

FIGURE 21: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 22: UNITED STATES SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 23: CANADA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 24: EUROPE SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 25: UNITED KINGDOM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 26: GERMANY SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 27: FRANCE SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 28: ITALY SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 29: SPAIN SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 30: NORDIC COUNTRIES SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 31: BELGIUM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 32: POLAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 33: REST OF EUROPE SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 34: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 35: CHINA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 36: JAPAN SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 37: INDIA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 38: SOUTH KOREA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 39: INDONESIA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 40: THAILAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 41: VIETNAM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 42: AUSTRALIA & NEW ZEALAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 43: REST OF ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 44: REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)

FIGURE 45: LATIN AMERICA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 46: MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FAQ’s

FAQs

As of 2022, the global skin cancer diagnostics market was valued at $3639.69 million.

Skin biopsy is set to be the fastest-growing screening type in the global skin cancer diagnostics market.

Request Customization
Request Customization
Request free sample